Looking back at treatments and outcomes for gastroenteropancreatic neuroendocrine tumors
Reviews past treatments for newly diagnosed adults with gastroenteropancreatic neuroendocrine tumors.
Plain-language title generated from the registry record
Registry title: A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Key facts
- Where
- East Hanover, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study looks at adults in the United States who were newly diagnosed with a GEP-NET between 2018 and 2025 and then started their first drug treatment for it. It uses insurance claims records.
- Age
- 18 years or older on the date treatment started
- Sex
- All sexes
- Disease stage
- Newly diagnosed gastroenteropancreatic neuroendocrine tumor (GEP-NET), with a diagnosis code recorded between 01 January 2018 and 31 December 2025
- Earlier treatment
- The first treatment for GEP-NET (somatostatin analogs, targeted therapy, PRRT or chemotherapy) is started on or after the diagnosis date. No GEP-NET treatment before that date.
Main reasons for not taking part
- GEP-NET found before the diagnosis date within the study period
- GEP-NET treatment before the start of first-line treatment
- Another primary cancer in the 12 months before treatment started
- Missing or invalid age or sex
- Invalid death date (on or before the treatment start date)
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 110 years old?
Source: NCT07635316, who can take part
Where in United States
- NovartisEast Hanover, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT07635316
- Record updated
- 15 October 2026
- Original description
This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.Read full original descriptionShow less
Treatment Patterns and Outcomes in GEP NET: A Retrospective Observational Cohort Study (PRIME Initiative)
This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.
Inclusion: Patients with ≥1 International Classification of Diseases Clinical Modification, 10th revision (ICD-10-CM) diagnosis code for GEP-NET between 01 January 2018 and 31 December 2025. The date of the first such claim will be defined as the diagnosis date; Initiation of first-line (1L) systemic therapy (i.e., somatostatin analogs [SSAs], targeted therapy, peptide receptor radionuclide therapy [PRRT], chemotherapy) indicated for GEP-NET on or after the date of diagnosis. The date of treatment initiation will be defined as the index date; Patients ≥18 years of age on the index date; Patients with ≥12 months (360 days) of continuous data availability (proxy for continuous health plan enrollment) prior to the index date, defined as:; ≥1 medical and pharmacy claim >12 months prior to the index date; AND; ≥1 medical and pharmacy claim within the first 6 months of the 12-month period prior to the index date; AND; ≥1 medical and pharmacy claim during the last 6 months of the 12-month period prior to the index date; AND; Patients with ≥1 month (30 days) of continuous data availability (proxy for continuous health plan enrollment) following the index date, defined as:; ≥ 1 pharmacy dispensing a GEP-NET treatment at any time during the post-index period, including the index date, reports data during the first month following the index date; ≥ 1 provider prescribing a GEP-NET treatment at any time during the post-index period, including the index date, reports data during the first month following the index date.
Exclusion: Patients with evidence of GEP-NET prior to the diagnosis date within the study period; Patients with evidence of GEP-NET treatment prior to the index date within the study period; Patients with other primary malignancies during the 12-month pre-index period; Patients with missing or invalid age or sex; Patients with invalid death date (i.e., death date ≤ index date).